The BCL-xL/BCL-2 Inhibitor Navitoclax Targets Myofibroblasts and Reduces Idiopathic Pulmonary Fibrosis (IPF) in Pre-Clinical Models

Y. He,T. Carr,J. Wetter,L. Leys,Z. Su, A. Williams,L. Olson, Z. Goldsmith, L. Dowding, S. Ashley,V. Morales-Tirado, P. Honore, L. Hazelwood

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE(2020)

引用 1|浏览20
暂无评分
关键词
idiopathic pulmonary fibrosis,myofibroblasts,inhibitor,pre-clinical
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要